Table 2.

Unadjusted effects of statin use on aldosterone and cortisol levels on sodium diet and angiotensin II interventions.

Hormonal measurements 317 subjects	Control group on HS* (85%)	Statin Group on HS* (15%)	p value	Control group on LS* (85%)	Statin Group on LS* (15%)	p value
Baseline Aldosterone nmol//L (ng/mL)	0.14 ± 0.09 (5.0 ± 3.3)	0.09 ± 0.04 (3.6 ± 1.5)	0.008	0.47 ± 0.27 (17.3 ± 9.9)	0.29 ± 0.16 (10.5 ± 5.9)	<0.001
Baseline Cortisol nmol/L (ug/dL )	278.7 ± 113.1 (10.1 ± 4.1)	289.7 ± 93.8 (10.5 ± 3.4)	0.69	314.5 ± 93.4 (11.4 ± 3.8)	10.1 ± 4.1 11.1 ± 3.1	0.70
Stimulated Aldo nmol//L (ng/mL)	0.39 ± 0.21 (13.9 ± 7.7)	0.30 ± 0.13 (11.0 ± 4.8)	0.003	1.08 ± 0.54 (39.0 ± 19.5)	0.70 ± 0.33 (25.3 ± 11.9)	<0.001
Stimulated Cortisol nmol/L (ug/dL )	259.3 ± 124.2 (9.4 ± 4.5)	251.1 ± 91.0 (9.1 ± 3.3)	0.74	262,1 ± 113.1 (9.5 ± 3.2)	223.8 ± 66.2 (9.10 ± 2.4)	0.26
Urinary Aldosterone ug/24h	11.7 ± 7.8	8.3 ± 4.6	<0.001	38.4 ± 23.3	27.0 ± 13.7	<0.001
Urinary Cortisol ug/24h	68.5 ± 32.2	66.2 ± 48.3	0.69	49.4 ± 24.8	50.0 ± 34.5	0.90

Data reported as mean ± SD, except as noted. HS indicates high sodium; LS, low sodium